^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Hepatocellular Cancer
    Drug Class:PD1 inhibitor +
    Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Oncol
    Title:

    PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

    Published date:
    08/02/2022
    Excerpt:
    A total of 47 HCC patients receiving the triple therapy were enrolled in this study….Patients with < 2 PD-L1+ CTCs at baseline had a higher objective response rate (ORR) and longer overall survival (OS) than those with ≥ 2 PD-L1+ CTCs (56.5% vs. 16.7%, p = 0.007; not reach vs. 10.8 months, p = 0.001, respectively)....Our study demonstrated that PD-L1+ CTCs could be a predictive biomarker for HCC patients receiving PD-1 inhibitors in combination with IMRT and antiangiogenic therapy.
    DOI:
    10.3389/fonc.2022.873830